JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB143673

Nonoxynol-9 (N-9), Nonionic surfactant

Be the first to review this product! Submit a review

|

(1 Publication)

MW 616.8 Da, Purity >98%. Nonionic surfactant. Inhibits proliferation (IC50 values are 2, 5, 54, 61 and 66 for P. berghei. P. falciparum, HeLa, HepG2 and C. albicans respectively). Shows spermicidal, bacteriostatic and bactericidal effects in vivo. .

View Alternative Names

Liver-specific organic anion transporter 1, OATP-2, OATP-C, SLC21A6, SLCO1B1, SO1B1_HUMAN, Sodium-independent organic anion-transporting polypeptide 2, Solute carrier family 21 member 6, Solute carrier organic anion transporter family member 1B1

1 Images
Chemical Structure - Nonoxynol-9 (N-9), Nonionic surfactant (AB143673)
  • Chemical Structure

Lab

Chemical Structure - Nonoxynol-9 (N-9), Nonionic surfactant (AB143673)

2D chemical structure image of ab143673, Nonoxynol-9 (N-9), Nonionic surfactant

Key facts

CAS number

14409-72-4

Purity

>98%

Form

Liquid

form

Molecular weight

616.8 Da

Molecular formula

C<sub>3</sub><sub>3</sub>H<sub>6</sub><sub>0</sub>O<sub>1</sub><sub>0</sub>

PubChem

72385

Nature

Synthetic

Biochemical name

Nonoxynol-9

Biological description

Nonionic surfactant. Inhibits proliferation (IC50 values are 2, 5, 54, 61 and 66 for P. berghei. P. falciparum, HeLa, HepG2 and C. albicans respectively). Shows spermicidal, bacteriostatic and bactericidal effects in vivo.

Canonical smiles

CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCOCCOCCO

InChi

InChI=1S/C33H60O10/c1-2-3-4-5-6-7-8-9-32-10-12-33(13-11-32)43-31-30-42-29-28-41-27-26-40-25-24-39-23-22-38-21-20-37-19-18-36-17-16-35-15-14-34/h10-13,34H,2-9,14-31H2,1H3

InChiKey

FBWNMEQMRUMQSO-UHFFFAOYSA-N

IUPAC Name

2-[2-[2-[2-[2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol

Product details

This product is a colourless or light yellow viscous liquid at room temperature.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

OATP1B1 also known as SLCO1B1 is a solute carrier organic anion transporter protein with a mass of approximately 85 kDa. This protein operates mechanically by transporting endogenous compounds and xenobiotics such as drugs across liver cell membranes. The primary expression of OATP1B1 occurs in the liver specifically on the basolateral membrane of hepatocytes. This localization facilitates its essential role in hepatic uptake of a variety of substances playing a critical role in pharmacokinetics.
Biological function summary

OATP1B1 contributes prominently to drug metabolism and clearance. It actively transports diverse substrates including bile acids bilirubin and drugs such as statins. While not part of a larger complex OATP1B1 functions alongside other hepatic transporters to ensure efficient clearance and detoxification processes in the liver. The activity of OATP1B1 is fundamental for maintaining drug concentrations within therapeutic ranges thereby protecting against toxicity.

Pathways

OATP1B1 is part of the hepatic drug metabolic pathway and the bile acid synthesis pathway. It works in coordination with other transporters like OATP1B3 and NTCP which also mediate hepatic uptake of organic anions and bile acids. The interaction among these transporters regulates the systemic levels of endogenous compounds and the clearance of therapeutic drugs influencing their efficacy and safety profiles.

OATP1B1 is linked to altered drug metabolism leading to statin-associated myopathy. Genetic variations in the OATP1B1 gene can reduce transporter function resulting in increased plasma concentration of statins which correlates with myopathy risk. Additionally OATP1B1 mutations may affect bilirubin handling contributing to conditions such as Rotor syndrome. Through these associations OATP1B1 interacts with other proteins affecting drug safety and disease states emphasizing its relevance in personalized medicine.

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Microorganisms 10: PubMed35208925

2022

Lactobacilli Strain Mixture Alleviates Bacterial Vaginosis through Antibacterial and Antagonistic Activity in -Infected C57BL/6 Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Soo-Im Choi,GaYeong Won,YongGyeong Kim,Chang-Ho Kang,Gun-Hee Kim
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com